<b>Background:</b> HER2-low breast cancer is a biologically heterogeneous subgroup in which hormone receptor (HR) expression critically shapes prognosis and treatment, but the underlying regulatory mechanisms remain unclear. This evidence concerns the gene ERBB2 and breast cancer.